E.E.S. 400 TABLETS Rx
Generic Name and Formulations:
Erythromycin (as ethylsuccinate) 400mg.
Arbor Pharmaceuticals, LLC
Indications for E.E.S. 400 TABLETS:
Treatment of susceptible infections including upper and lower respiratory, skin and skin structure, genitourinary, Legionnaires' disease, pertussis, listeriosis. Prophylaxis for rheumatic fever attacks in penicillin-allergic patients.
1.6g/day in 2, 3, or 4 evenly divided doses; max 4g/day. Legionnaires: 1.6–4g/day in divided doses. Prophylaxis: 400mg twice daily. See full labeling.
Mild-to-moderate infections: 30–50mg/kg/day in 2, 3, or 4 evenly divided doses; may double dose in severe infections. See full labeling.
Concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine, statins (eg, lovastatin, simvastatin).
Avoid in proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); risk of QT prolongation. Myasthenia gravis. Hepatic impairment. Elderly. Infants: risk of infantile hypertrophic pyloric stenosis; monitor for vomiting or irritability with feeding. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate theophylline (reduce dose of theophylline), digoxin, oral anticoagulants, hexobarbital, phenytoin, valproate. May potentiate CYP3A substrates (eg, triazolam, midazolam, statins [rhabdomyolysis], sildenafil [reduce dose of sildenafil], colchicine [reduce starting dose of colchicine, max dose should be lowered; monitor], verapamil, amlodipine, diltiazem, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine); consider dose adjustments and monitor. May be antagonized by theophylline. Hypotension, bradyarrhythmias, lactic acidosis with verapamil. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics; avoid. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation, C. difficile-associated diarrhea, superinfection (discontinue if occurs).
Granules—100mL, 200mL; Tabs—100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC